In the past decade significant advances have been made in developing stem cell therapies for the potential treatment of a range of diseases and conditions. Drug approval regulators have responded by issuing guidance documents for the development of such therapies. The approach, and testing required, to prove preclinical efficacy and safety of stem cell therapies will vary according to the unique characteristics of each therapy. Participants of this live webinar will gain an understanding of a typical preclinical development program that will provide regulatory comfort to allow progression of clinical trials.
DATE: Monday, March 4, 2013
TIME:
11:00 am EDT | 2:00 pm PDT
DURATION: 1 hour
COST: Free
Speakers:
- Michaela Sharpe, Ph.D., Director, Nonclinical Development, OakMore Solutions Ltd
- Frank Bonner, CEO, Stem Cells for Safer Medicine
- Leigh Berryman, B.Sc (Hons), M.S.B., C.Biol., Reg. Tox., RQAP-GLP, CEO, Maccine Pte Ltd
- Kishore Bhakoo, Ph.D., Director, Translational Imaging Industrial Laboratory; Head, Translational Molecular Imaging Group, Singapore Bioimaging Consortium, Agency for Science, Technology and Research
View detailed webinar agenda
